Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Authors: Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prébet, Sang‐Min Lee, Gary J. Schiller, Shira Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen Seiter, Andrew H. Wei, Stéphane de Botton, Montserrat Arnán, Will Donnellan, Anthony P. Schwarer, Christian Récher, Brian A. Jonas, P. Brent Ferrell, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jörge E. Cortes - The Lancet 2022 cited by 117